PharmaPoint: Irritable Bowel Syndrome (IBS) - Global Drug Forecast and Market Analysis to 2026

  • ID: 4494873
  • Report
  • Region: Global
  • 185 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Allergan
  • Ardelyx
  • Astellas
  • Ironwood Pharmaceuticals
  • Salix
  • Sebela Pharmaceuticals
  • MORE
PharmaPoint: Irritable Bowel Syndrome (IBS) - Global Drug Forecast and Market Analysis to 2026

Summary

Irritable bowel syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. IBS is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least three months. IBS is classified into three main subtypes, according to the predominant bowel habit: constipation-predominant (IBS-C), diarrhea-predominant (IBS-D), and mixed-presentation (IBS-M) IBS.

The IBS treatment landscape remains largely underserved, and ample opportunity exists for pharmaceutical companies to address the numerous unmet needs in this therapy area. Based on insights gathered from primary and secondary research, the author anticipates that two of the new drugs, tenapanor and SYN-010, will have an initial slow uptake, as opposed to Trulance (plecanatide), which has a similar mode of action (MOA) to that of Linzess/Constella (linaclotide). The sales are expected to grow steadily over the forecast period, primarily due to the increased prevalent population and the launch of novel agents to treat IBS-C.

This model covers the market forecast for IBS marketed therapies and late-stage pipeline candidates. The base year of this model is 2016 and the forecast period is 2017-2026.

Scope
  • Overview of IBS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline market revenue from 2016-2026 for IBS. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting prescription drug sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global prescription drug market for IBS. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global prescription drug market for IBS.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the prescription drug market for IBS in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan
  • Ardelyx
  • Astellas
  • Ironwood Pharmaceuticals
  • Salix
  • Sebela Pharmaceuticals
  • MORE
1 Table of Contents

2 Executive Summary
2.1 The IBS Market Expected to Experience Solid Growth from 2016-2026
2.2 Companies Leverage Partnerships to Successfully Develop and Commercialize IBS Products
2.3 The IBS Market is Characterized by Significant Unmet Needs
2.4 Products With Improved Efficacy Will Have Significant Opportunities in the IBS Market
2.5 The Potential Introduction of Late-Stage Pipeline Products Will Drive Growth in the IBS Market
2.6 What Do Physicians Think

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Classification or Staging Systems
4.3 Symptoms
4.4 Prognosis
4.5 Quality of Life

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for IBS (2016-2026)
5.5.1 Total Prevalent Cases of IBS
5.5.2 Diagnosed Prevalent Cases of IBS
5.5.3 Age-Specific Diagnosed Prevalent Cases of IBS
5.5.4 Sex-Specific Diagnosed Prevalent Cases of IBS
5.5.5 Diagnosed Prevalent Cases of IBS by Clinical Subtype
5.5.6 Diagnosed Prevalent Cases of IBS Clinical Subtype by Comorbidity
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis

6 Disease Management
6.1 Diagnosis Overview
6.2 Treatment Overview
6.2.1 Treatment Guidelines
6.2.2 Clinical Practice
6.3 US
6.4 5EU
6.5 Japan

7 Competitive Assessment
7.1 Overview
7.2 Product Profiles - Major Brands, IBS-C Therapy
7.2.1 Linzess (linaclotide)
7.2.2 Amitiza (lubiprostone)
7.3 Product Profiles - Major Brands, IBS-D Therapy
7.3.1 Xifaxan (rifaximin)
7.3.2 Viberzi (eluxadoline)
7.3.3 Lotronex (alosetron)
7.3.4 Irribow (ramosetron)
7.4 Product Profiles - Therapeutic Agents for All IBS Clinical Subtypes
7.4.1 Antidepressants
7.5 Other Minor Therapeutic Classes
7.5.1 OTCs and Non-pharmacological Treatment Options for IBS
7.5.2 Off-Label Prescription Treatment Alternatives for IBS

8 Unmet Needs and Opportunity Analysis
8.1 Overview
8.2 More Efficacious Prescription Drugs Indicated for IBS
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Novel Therapies for IBS-D Patients
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Drugs Specifically Approved for IBS-M Patients
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Therapies to Address Abdominal Pain and Bloating Associated with IBS
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
8.6 More Accurate Diagnosis of Appropriate IBS Clinical Subtype
8.6.1 Unmet Need
8.6.2 Gap Analysis
8.6.3 Opportunity

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 Trulance (plecanatide)
9.2.2 Tenapanor
9.2.3 SYN-010 (oral modified-release lovastatin lactone)
9.3 Other Drugs in Development

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Allergan
10.3.2 Astellas
10.3.3 Ironwood Pharmaceuticals
10.3.4 Takeda
10.3.5 Sucampo
10.3.6 Sebela Pharmaceuticals
10.3.7 Salix
10.3.8 Synergy
10.3.9 Ardelyx
10.3.10 Synthetic Biologics

11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers

12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included In Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - KOLs Interviewed for this Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Directors
12.6.3 Epidemiologists
12.6.4 Global Director of Therapy Analysis and Epidemiology
12.6.5 Global Head and EVP of Healthcare Operations and Strategy
12.7 About
12.8 Contact
12.9 Disclaimer

List of Tables
Table 1: Irritable Bowel Syndrome (IBS): Key Metrics in Seven Major Pharmaceutical Markets
Table 2: Symptoms of IBS
Table 3: Risk Factors and Comorbidities for IBS
Table 4: Comparison of the IBS Diagnostic Criteria Used in Epidemiological Studies
Table 5: 7MM, Total Prevalent Cases of IBS, Both Sexes, Ages =18 Years, N, Selected Years from 2016-2026
Table 6: 7MM, Diagnosed Prevalent Cases of IBS, Both Sexes, Ages =18 Years, N, Selected Years from 2016-2026
Table 7: 7MM, Diagnosed Prevalent Cases of IBS by Clinical Subtypes, Both Sexes, Ages =18 Years, N, 2016
Table 8: 7MM, Diagnosed Prevalent Cases of IBS Subtypes with Comorbidity, Both Sexes, Ages =18 Years, N, 2016
Table 9: Summary of the Various Diagnostic Criteria Used for the Diagnosis of IBS
Table 10: Treatment Guidelines for IBS
Table 11: Country Profile - US
Table 12: Country Profile - 5EU
Table 13: Country Profile - Japan
Table 14: Leading Treatments for IBS, 2017
Table 15: Product Profile - Linzess
Table 16: Efficacy Responder Rates in Linzess’ Two Placebo-Controlled IBS-C Trials: At Least Nine Out of 12 Weeks
Table 17: Efficacy Responder Rates in Linzess’ Two Placebo-Controlled IBS-C Trials: At Least Six Out of 12 Weeks
Table 18: Safety of Linzess - Most Frequently Reported AEs
Table 19: Linzess SWOT Analysis, 2017
Table 20: Product Profile - Amitiza
Table 21: Safety of Amitiza - Most Frequently Reported AEs
Table 22: Amitiza SWOT Analysis, 2017
Table 23: Product Profile - Xifaxan
Table 24: Efficacy Analysis of Xifaxan in Target 1 and 2 Trials
Table 25: Efficacy Responder Rates in Target 3 Trial in a Given Week for at Least 2 Weeks During Weeks 3 to 6 of the Double-Blind, First Repeat Treatment Phase
Table 26: Safety Analysis of Xifaxan in Target 1 and 2 Trials
Table 27: Safety Analysis of Xifaxan in Target 3 Trial
Table 28: Xifaxan SWOT Analysis, 2017
Table 29: Product Profile - Viberzi
Table 30: Efficacy Analysis of Viberzi in IBS-3001 and IBS-3002 Trials
Table 31: Common AEs of Viberzi
Table 32: Viberzi SWOT Analysis, 2017
Table 33: Product Profile - Lotronex
Table 34: Safety of Lotronex - Most Frequently Reported AEs
Table 35: Lotronex SWOT Analysis, 2017
Table 36: Product Profile - Irribow
Table 37: Irribow SWOT Analysis, 2017
Table 38: Antidepressants in IBS, SWOT Analysis, 2017
Table 39: Summary of Minor Therapeutic Classes, 2016
Table 40: Mechanisms of Action and AEs of Minor Therapeutic Classes, 2016
Table 41: Product Profile - Trulance
Table 42: Trulance SWOT Analysis, 2017
Table 43: Product Profile - Tenapanor
Table 44: T3MPO-1 Trial-Tenapanor 6 of 12 Week Treatment Results
Table 45: T3MPO-2 Trial-Tenapanor 6 of 12 Week Treatment Results
Table 46: Tenapanor SWOT Analysis, 2017
Table 47: Product Profile - SYN-010
Table 48: SYN-010 SWOT Analysis, 2017
Table 49: Other Drugs in Development for IBS, 2017
Table 50: Key Companies in the IBS Market in the 7MM, 2017
Table 51: Allergan’s IBS Portfolio Assessment, 2017
Table 52: Astellas’ IBS Portfolio Assessment, 2017
Table 53: Ironwood’s IBS Portfolio Assessment, 2017
Table 54: Takeda’s IBS Portfolio Assessment, 2017
Table 55: Sucampo’s IBS Portfolio Assessment, 2017
Table 56: Prometheus/Sebela Ireland’s IBS Portfolio Assessment, 2017
Table 57: Salix’s IBS Portfolio Assessment, 2017
Table 58: Synergy’s IBS Portfolio Assessment, 2017
Table 59: Ardelyx’s IBS Portfolio Assessment, 2017
Table 60: Synthetic Biologics’ IBS Portfolio Assessment, 2017
Table 61: IBS - Global Drivers and Barriers, 2016-2026
Table 62: Key Events Impacting Sales for IBS in the US, 2016-2026
Table 63: IBS - US Drivers and Barriers, 2016-2026
Table 64: Key Events Impacting Sales for IBS in the 5EU, 2016-2026
Table 65: IBS - 5EU Drivers and Barriers, 2016-2026
Table 66: Key Events Impacting Sales for IBS in Japan, 2016-2026
Table 67: IBS - Japan Drivers and Barriers, 2016-2026
Table 68: Key Historical and Projected Launch Dates for IBS
Table 69: Key Patent Expiry Dates for IBS
Table 70: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global (7MM) Sales for IBS by Region, 2016 and 2026
Figure 2: Analysis of the Company Portfolio Gap in IBS During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Products Under Development for IBS
Figure 4: IBS Pathophysiology
Figure 5: 7MM, Age-Standardized Diagnosed Prevalence of IBS, Ages =18 Years, 2016
Figure 6: 7MM, Sources Used and Not Used, Total Prevalent Cases of IBS
Figure 7: 7MM, Sources Used, Diagnosed Prevalent Cases of IBS
Figure 8: 7MM, Sources Used, Diagnosed Prevalent Cases of IBS Clinical Subtypes
Figure 9: 7MM, Sources Used, Diagnosed Prevalent Cases of IBS With Comorbidity
Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages =18 Years, N, 2016
Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of IBS, Both Sexes, Ages =18 Years, N, 2016
Figure 12: Unmet Need and Opportunity in IBS, 2017
Figure 13: Bullseye Diagram of Products in Clinical Development for IBS, 2017
Figure 14: Key Phase II/III Trials for Promising Pipeline Agents for IBS, 7MM, 2016-2026
Figure 15: Competitive Assessment of the Late-Stage Pipeline Agents that the author Expects to be Licensed for the Treatment of IBS in the Forecast Period
Figure 16: Clinical and Commercial Positioning of Trulance
Figure 17: Clinical and Commercial Positioning of Tenapanor
Figure 18: Clinical and Commercial Positioning of SYN-010
Figure 19: Analysis of the Company Portfolio Gap in IBS During the Forecast Period
Figure 20: Global (7MM) Sales for IBS by Region, 2016 and 2026
Figure 21: Global (7MM) Sales for IBS by Drug, 2016 and 2026
Figure 22: Sales for IBS in the US, 2016 and 2026
Figure 23: Sales for IBS in the US by clinical subtype, 2016-2026
Figure 24: Sales for IBS in the 5EU, 2016 and 2026
Figure 25: Sales for IBS in the 5EU by clinical subtype, 2016-2026
Figure 26: Sales for IBS in Japan, 2016 and 2026
Figure 27: Sales for IBS in Japan by clinical subtype, 2016-2026
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Allergan
  • Astellas
  • Ironwood Pharmaceuticals
  • Takeda
  • Sucampo
  • Sebela Pharmaceuticals
  • Salix
  • Synergy
  • Ardelyx
  • Synthetic Biologics
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll